UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018530
Receipt number R000021443
Scientific Title Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants'
Date of disclosure of the study information 2015/08/03
Last modified on 2018/10/11 15:16:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants'

Acronym

Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants'

Scientific Title

Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants'

Scientific Title:Acronym

Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants'

Region

Japan


Condition

Condition

NA

Classification by specialty

Child

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To consider the appropriate injection needle and the insertion depth at the time of the subcutaneous and intramuscular vaccination in Japanese infants

Basic objectives2

Others

Basic objectives -Others

To consider the appropriate injection needle and the insertion depth at the time of the subcutaneous and intramuscular vaccination in Japanese infants

Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

NA

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

Using an ultrasonic echo, obtains the tomographic image information about the structure of skin and muscle tissue .

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

3 months-old <=

Age-upper limit

15 months-old >=

Gender

Male and Female

Key inclusion criteria

(1) Infant whose written consent form is obtained from his/her representative for participation in this study.
(2) Infant obtained written consent form from his.her representative at the age of 2 months old at enrolment of main study.
(3) Infant who has grown stably after birth. Even if an infant was suffering not severe transient acute disease or not severe chronic disease(common cold, upper respiratory inflammation, etc), participation in this study would be allowed when investigator medically judges the disease dose not affect the measurement items.
(4) Japanese(the infant was born in Japan, and his/her all 4 grandparents are Japnese with speaking Japanease)

Key exclusion criteria

(1) infant who has an abnormality in the measurement target site.
(2) infant with who investigator judges stable and circumference measurements and image inspection is difficult.
(3) infant who is suffering from severe acute and chronic disease.
(4) infant who has an experience of any damage in the arms or legs.
(5) infant who has or experienced all of neurological or muscle disease.
(6) Other, infant who investigator judges ineligible as a subject.
(7) infant whose written consent form is not obtained by his/her representative's own free will.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tesuo Nakayama

Organization

Kitasato Univercity, Kitasato Institute for Life Science

Division name

Department of Infection Control and Immunology, Laboratory of Viral Infection I

Zip code


Address

5-9-1 Shirokane, Minato-ku, Tokyo 108-8641

TEL

03-3444-6161

Email

tetsuo-n@lisci.kitasato-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Keitaro Yatabe

Organization

Japan Vaccine Co.,Ltd

Division name

Clinical Development & Medical Affairs Division, Medical Affairs Group

Zip code


Address

6 Yonbancho Chiyoda-ku Tokyo 102-0081 Japan

TEL

03-5213-2735

Homepage URL


Email

yatabe.keitaro.d7@japanvaccine.co.jp


Sponsor or person

Institute

Japan Vaccine Co.,Ltd

Institute

Department

Personal name



Funding Source

Organization

Japan Vaccine Co.,Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

静岡厚生連 静岡厚生病院(静岡県)
東京都済生会中央病院(東京都)


Other administrative information

Date of disclosure of the study information

2015 Year 08 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2015 Year 06 Month 30 Day

Date of IRB


Anticipated trial start date

2015 Year 08 Month 26 Day

Last follow-up date

2016 Year 10 Month 17 Day

Date of closure to data entry

2016 Year 10 Month 17 Day

Date trial data considered complete

2017 Year 04 Month 21 Day

Date analysis concluded

2017 Year 08 Month 31 Day


Other

Other related information

Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants(UMIN000017591)'


Management information

Registered date

2015 Year 08 Month 03 Day

Last modified on

2018 Year 10 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021443


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name